Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants

SIMPLE SUMMARY: In our study, we retrospectively collected data of patients with germline CDKN2A pathogenic variants who received targeted therapy for advanced melanoma across four European centers. Since loss of CDKN2A function may intrinsically limit the activity of MAPK-directed targeted therapy,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers (Basel)
Hauptverfasser: Spagnolo, Francesco, Dalmasso, Bruna, Tanda, Enrica, Potrony, Miriam, Puig, Susana, van Doorn, Remco, Kapiteijn, Ellen, Queirolo, Paola, Helgadottir, Hildur, Ghiorzo, Paola
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2021
Schlagworte:
Communication
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8157545/
https://ncbi.nlm.nih.gov/pubmed/34069952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102440
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge